Table 3 Incremental cost-effectiveness ratio of the intervention and the sensitivity analysis
Cost of HIV care in the intervention arm (USD) | Cost of HIV care in the control arm (USD) | Cost difference (USD) | Effectiveness (%) | ICER ($US/ additional patient with undetectable viral load) | ||
|---|---|---|---|---|---|---|
Main model | 338.70 | 172.68 | 166.02 | 0.117 | 1419 | |
Sensitivity analysis | Dolutegravir-based combination | 338.70 | 172.68 | 166.02 | 0.089 | 1865 |
Changes in the cost of ART (±25% [L, U]) | 317.00 & 360.4 | 145.35 & 200.00 | 171.65 & 160.40 | 0.117 | 1467 & 1371 | |
Changes in the cost of non-ART (±25% [L, U]) | 325.52 & 351.88 | 170.54 & 174.82 | 154.98 & 177.06 | 0.117 | 1325 & 1513 | |
Changes in the CD4 and viral load tests costs (±25% [L, U]) | 299.78 & 377.63 | 162.95 & 182.41 | 136.83 & 195.22 | 0.117 | 1169 & 1669 | |
Triannual CD4 and viral load tests for the intervention arm | 299.80 | 172.68 | 127.12 | 0.117 | 1086 | |
Changes in viral load tests cost (±25% [L, U]) | 305.37 & 372.03 | 164.36 & 181.01 | 141.01 & 191.02 | 0.117 | 1205 & 1632 | |
Changes in the cost of ART, CD4, and viral load tests (±25% [L, U]) | 278.08 & 399.32 | 135.62 & 209.74 | 142.46 & 189.58 | 0.117 | 1218 & 1620 |